Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the italian breast cancer adjuvant study group O2 randomized trial

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2718-2727

  Boccardo, Francesco ^a   Rubagotti, A ^a   Amoroso, D ^a   Mesiti, M ^a   Romeo, D ^a   Sismondi, P ^a   Giai, M ^a   Genta, F ^a   Pacini, P ^a   Distante, V ^a   Bolognesi, A ^a   Aldrighetti, D ^a   Farris, A ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OVARIECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

EID: 18344409979     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2718     Document Type: Article

References (32)

1. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlight: International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601-1608, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomized trials. Lancet 348:1189-1196, 1996
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
4. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Lancet 341:1293-1298, 1993
5. Kaufmann M, Jonat W, Abel U, et al: Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11:454-460, 1993
6. Nomura Y, Tashiro H, Hisamatsu K, et al: A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors. Cancer 61:2168-2175, 1988
7. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol 8:1310-1320, 1990
8. Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients: An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer 28:673-680, 1992
9. Boccardo F, Rubagotti A, Amoroso D, et al: Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA) Trials, in Senn H-J, Gelber RD, Goldhirsch A, et al (eds): Adjuvant Therapy of Breast Cancer VI (vol 152): Recent Results in Cancer Research, Heidelberg, Germany, Springer-Verlag, 1998, pp 453-470
10. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1998
11. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1049 cases, of which 359 have been followed 15 years. Br J Cancer 11:359-363, 1957
12. Silvestrini R, Daidone MG, Valagussa P, et al: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165-1171, 1989
13. Hedley DW, Clark GM, Cornelisse CJ, et al: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast: Report of the DNA Cytometry Consensus Conference. Cytometry 14:482-485, 1993
14. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer: Report of the Second EORTC Workshop, 16-17 March 1979, Netherlands Cancer Institute. Eur J Cancer 16:1513-1515, 1980
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:92-115, 1985
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612, 1976
19. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
20. Mantel N, Byar DP: Evaluation of response-time data involving transient states: An illustration using heart-transplant data. J Am Stat Assoc 69:81-86, 1974
21. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference - International Breast Cancer Study Group. J Clin Oncol 16:1358-1362, 1998
22. Jakesz R. Hausmaninger H, Samonigg H, et al: Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 250)
23. Klijn JGM, Beex L, Mauriac L, et al: Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer: Final results of EORTC Study 10881. Ann Oncol 9:11, 1998 (suppl 4, abstr 540)
24. Rutqvist LE: Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Res Campaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group, & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O). Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 251)
25. Davidson N, O'Neill A, Vukov A, et al: Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 18:67a, 1999 (abstr 249)
26. Boccardo F, Blamey RW, Klijn JGM, et al: LHRH-agonist (LHRH-A) + tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC): Results of a meta-analysis of four trials. Proc Am Soc Clin Oncol 18:110a, 1999 (abstr 416)
27. Jordan VC, Fritz NF, Langan-Fahey S, et al: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488-1491, 1991
28. Chang J. Powles TJ, Ashley SE, et al: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7:671-675, 1996
29. Pagani O, O'Neill A, Castiglione M, et al: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998
30. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63:799-803, 1991
31. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998
32. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994